Press Releases

Date Title and Summary  
Toggle Summary Calvin B. Harley to Retire as Chief Scientific Officer of Geron
Continues as Senior Advisor to Company MENLO PARK, Calif., September 8, 2009 - Geron Corporation (Nasdaq: GERN) today announced that Calvin B. Harley, Ph.D., the company's chief scientific officer (CSO) for telomerase technologies, will retire on September 15, 2009. Dr.
Toggle Summary Corning Incorporated and Geron Corporation Showcase New Synthetic Surface Matrices to Enhance Stem Cell Growth
Results of collaborative research to be shared at 2009 World Stem Cell Summit CORNING, N.Y. & MENLO PARK, Calif., September 21, 2009 - Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to
Toggle Summary Data Show Geron´s Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection
Study Also Shows GRNOPC1 Does Not Amplify Neuropathic Pain Like Other Neural Progenitor Cells Injected into Spinal Cord MENLO PARK, Calif., Nov. 7, 2007 – Geron Corporation (Nasdaq: GERN) today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)–based therapeutic for
Toggle Summary Dr. Thomas Okarma Resumes Direct Leadership of Geron´s Oncology Drug Development Activities
MENLO PARK, Calif., Jan. 25, 2008 – Geron Corporation (NASDAQ: GERN) today announced that President and Chief Executive Officer Thomas B. Okarma, Ph.D., M.D., has resumed his operational leadership of the company’s oncology drug development activities.
Toggle Summary Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies
Results From Two Separate Clinical Studies Suggest Disease-Modifying Activity MENLO PARK, Calif. , Sept. 02, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the publication of two papers in The New England Journal of Medicine (NEJM) in which the company’s telomerase
Toggle Summary FDA Places Geron’s GRNOPC1 IND on Clinical Hold
MENLO PARK, Calif., May 14, 2008 – Geron Corporation (Nasdaq: GERN) announced today that the company received verbal notice today from the FDA that the company's Investigational New Drug (IND) submission for GRNOPC1, a cell therapy for spinal cord injury, has been placed on clinical hold.
Toggle Summary GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
Click here for Backgrounder ( link to PDF ) CHALFONT ST. GILES, UK & MENLO PARK, Calif., June 30, 2009 - GE Healthcare, a unit of General Electric Company (NYSE: GE), and Geron Corporation (Nasdaq: GERN) today announced that they have entered into a global exclusive license and alliance agreement
Toggle Summary Geron 2017 Annual Meeting of Stockholders to be Held on May 9
First Quarter 2017 Financial Results Expected Same Day MENLO PARK, Calif. , April 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2017 Annual Meeting of Stockholders, on Tuesday, May 9, 2017 , at 4:00 p.m. PDT . Geron’s stockholders are invited to attend the Annual
Toggle Summary Geron 2018 Annual Meeting of Stockholders to be Held on May 15
First Quarter 2018 Financial Results to be Announced on May 10 MENLO PARK, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2018 Annual Meeting of Stockholders, on Tuesday, May 15, 2018 , at 4:00 p.m. PDT . Geron’s stockholders are invited to attend the
Toggle Summary Geron Acknowledges Letter to its Stockholders from BioTime
MENLO PARK, Calif., October 19, 2012 -- Geron Corporation (Nasdaq: GERN) today acknowledged the public release by BioTime, Inc. (NYSE: BTX) of a letter to Geron's stockholders regarding Geron's stem cell assets. Geron's Board of Directors has, since the announcement that Geron would be